{"count": 2, "results": [{"_id": "35815185", "pmid": 35815185, "title": "Are STK11 polymorphisms a predictor of the response to metformin in polycystic ovarian syndrome?", "journal": "Biomed Rep", "authors": ["Hamadneh J", "Amarin Z", "Alchalabi H", "Al-Bayyari N", "Hamadneh S"], "date": "2022-06-21T00:00:00Z", "doi": "10.3892/br.2022.1553", "meta_date_publication": "2022 Aug", "meta_volume": "17", "meta_issue": "2", "meta_pages": "70", "score": 50251.305, "text_hl": "There were statistically significant improvements following @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ therapy in menstrual frequency, @<m>DISEASE_Blood_Loss_Surgical</m> @DISEASE_MESH:D016063 @@@blood loss@@@, @DISEASE_Acne_Vulgaris @DISEASE_MESH:D000152 @@@acne@@@, ultrasound findings, and a decrease in BMI, @DISEASE_Acne_Vulgaris @DISEASE_MESH:D000152 @@@acne@@@, and @DISEASE_Hirsutism @DISEASE_MESH:D006628 @@@hirsutism@@@, but not in @DISEASE_Alopecia @DISEASE_MESH:D000505 @@@alopecia@@@. ", "citations": {"NLM": "Hamadneh J, Amarin Z, Alchalabi H, Al-Bayyari N, Hamadneh S. Are STK11 polymorphisms a predictor of the response to metformin in polycystic ovarian syndrome? Biomed Rep. 2022 Aug;17(2):70. PMID: 35815185", "BibTeX": "@article{35815185, title={Are STK11 polymorphisms a predictor of the response to metformin in polycystic ovarian syndrome?}, author={Hamadneh J and Amarin Z and Alchalabi H and Al-Bayyari N and Hamadneh S}, journal={Biomed Rep}, volume={17}, number={2}, pages={70}}"}}, {"_id": "28270711", "pmid": 28270711, "pmcid": "PMC5309901", "title": "Provider Decisions and Patient Outcomes After Premature Metformin Discontinuation", "journal": "Diabetes Spectr", "authors": ["Bradley JN", "Edwards KL", "Gunter JT", "Weideman RA", "Kelly KC"], "date": "2017-02-01T00:00:00Z", "doi": "10.2337/ds15-0049", "meta_date_publication": "2017 Feb", "meta_volume": "30", "meta_issue": "1", "meta_pages": "17-22", "score": 50049.324, "text_hl": "Providers should consider the expanded recommendations for the use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @SPECIES_9606 @@@patients@@@ with mild to moderate stable @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@renal dysfunction@@@ to help such @SPECIES_9606 @@@patients@@@ avoid @DISEASE_Weight_Gain @DISEASE_MESH:D015430 @@@weight gain@@@, @DISEASE_Hypoglycemia @DISEASE_MESH:D007003 @@@hypoglycemia@@@, @<m>DISEASE_Blood_Loss_Surgical</m> @DISEASE_MESH:D016063 @@@loss of blood glucose control@@@, and increased costs.", "citations": {"NLM": "Bradley JN, Edwards KL, Gunter JT, Weideman RA, Kelly KC. Provider Decisions and Patient Outcomes After Premature Metformin Discontinuation Diabetes Spectr. 2017 Feb;30(1):17-22. PMID: 28270711", "BibTeX": "@article{28270711, title={Provider Decisions and Patient Outcomes After Premature Metformin Discontinuation}, author={Bradley JN and Edwards KL and Gunter JT and Weideman RA and Kelly KC}, journal={Diabetes Spectr}, volume={30}, number={1}, pages={17-22}}"}}]}